Navigation Links
SCOLR Pharma, Inc. Announces Initial Shipments of its Nutritional Products
Date:12/23/2011

BOTHELL, Wash., Dec. 23, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTCQB: SCLR) today announced that it has  received and shipped initial retail orders for its extended-release nutritional products based on the Company's proprietary CDT® oral drug delivery platform. The shipments represent SCOLR's first significant direct retail sales of its nutritional products.

Stephen J. Turner, SCOLR Pharma's President and CEO, said, "Shipment of these initial orders marks an important milestone for SCOLR as we continue to focus on growing our nutritional products business into a sustainable source of revenue. We are gratified by the response we have had with retailers and confident that our products are greeted well by consumers."

Turner said SCOLR intends to provide investors with future updates on its nutritional business activities in conjunction with its quarterly announcements of financial results and in its periodic reports filed with the Securities and Exchange Commission.

About SCOLR Pharma:

Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http://www.scolr.com/.

Forward looking statements:                                              

Any statements made in this press release that relate to future plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These forward looking statements include statements regarding anticipated developments in the Company's nutritional business.  Factors that could cause these forward-looking statements to differ from actual results include delays in manufacturing, labeling or shipment of products, order revisions, or variations in retailer's marketing plans, and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission.  SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.

Contacts:

Investor Relations:
SCOLR Pharma, Inc.                                            
425.368.1050


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. SCOLR Pharma, Inc. Reports Third Quarter 2009 Financial Results
4. SCOLR Pharma, Inc. Receives Notices From NYSE Amex LLC Regarding Compliance Plan and Listing Standards
5. SCOLR Pharma, Inc. Licenses Dietary Supplements
6. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
7. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
8. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
9. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
10. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
11. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Jan. 23, 2017  Delcath Systems, Inc. (NASDAQ: ... the treatment of primary and metastatic liver cancers, today ... CRNP, President and Chief Executive Officer of Delcath will ... Capital Markets, Thirteenth Annual Investor Conference at the Boca ... Florida , on Tuesday, January 31, 2017 at ...
(Date:1/23/2017)... , January 23, 2017 ... (r enal) y el riesgo ... de a pabetalone    Resverlogix Corp. ... resultados preliminares de un ensayo en fase 1 con ... de riñón (renal) severa. Los datos demostraron unos resultados ...
(Date:1/23/2017)... The global  anxiety disorders and depression treatment market  is expected to reach ... worldwide is anticipated to drive the market growth in the coming years. Increasing ... in the recent years. Continue Reading ... ... ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... The iaedp Foundation, recognized ... treatment providers who treat the full spectrum of eating disorder problems, proudly announces ... Council consists of the leading eating disorder treatments centers located throughout the U.S. ...
(Date:1/23/2017)... ... ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy of dry ... new water infrastructure a number one priority. “As we usher in a new national ... become a top priority of our new political change agents.” Kleyne pointed out that ...
(Date:1/23/2017)... ... January 23, 2017 , ... METTLER TOLEDO has ... Chemistry by Applying Simple PAT Tools . , Crystallization is a ... the desired product. Chemists now spend more time developing better intermediate and ...
(Date:1/23/2017)... , ... January 23, 2017 , ... "ProRandom is a set of camera tools that ... dynamic looks in Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... two layers of text with video footage. ProRandom works by using a virtual camera ...
(Date:1/23/2017)... ... 23, 2017 , ... Gynecology Associates of Gwinnett (GAoG) has ... for women of all ages. The staff of Gynecology Associates of Gwinnett ... from routine health screenings to diagnosing and treating female concerns including menopause, urinary ...
Breaking Medicine News(10 mins):